BJBoyue Jiang

Boyue Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boyue Jiang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Fangqing Zhao

    Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China

    1 shared publication
  • Fei Xiao

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication
  • Gaoyuan Sun

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication
  • Hexin Li

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing China

    1 shared publication
  • Hongyuan Cui

    Department of General Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication
  • Jianfu Cao

    Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Gut microbiome and metabolome characteristics of patients with cholesterol gallstones suggest the preventive potential of prebiotics

    by Ye Liu, Hexin Li, Tianhan Sun, Gaoyuan Sun, Boyue Jiang, Meilan Liu, Qing Wang, Tong Li, Jianfu Cao, Li Zhao, et al.

    Cholesterol gallstones (CGS) still lack effective noninvasive treatment. The etiology of experimentally proven cholesterol stones remains underexplored. This cross‐sectional study aims to comprehensively evaluate potential biomarkers in patients with gallstones and assess the effects of microbiome‐targeted interventions in mice. Microbiome taxonomic profiling was conducted on 191 samples via V3−V4 16S rRNA sequencing. Next, 60 samples (30 age‐ and sex‐matched CGS patients and 30 controls) were selected for metagenomic sequencing and fecal metabolite profiling via liquid chromatography‐mass spectrometry. Microbiome and metabolite characterizations were performed to identify potential biomarkers for CGS. Eight‐week‐old male C57BL/6J mice were given a lithogenic diet for 8 weeks to promote gallstone development. The causal relationship was examined through monocolonization in antibiotics‐treated mice. The effects of short‐chain fatty acids such as sodium butyrate, sodium acetate (NaA), sodium propionate, and fructooligosaccharides (FOS) on lithogenic diet‐induced gallstones were investigated in mice. Gut microbiota and metabolites exhibited distinct characteristics, and selected biomarkers demonstrated good diagnostic performance in distinguishing CGS patients from healthy controls. Multi‐omics data indicated associations between CGS and pathways involving butanoate and propanoate metabolism, fatty acid biosynthesis and degradation pathways, taurine and hypotaurine metabolism, and glyoxylate and dicarboxylate metabolism. The incidence of gallstones was significantly higher in the Clostridium glycyrrhizinilyticum group compared to the control group in mice. The grade of experimental gallstones in control mice was significantly higher than in mice treated with NaA and FOS. FOS could completely inhibit the formation of gallstones in mice. This study characterized gut microbiome and metabolome alterations in CGS. C. glycyrrhizinilyticum contributed to gallstone formation in mice. Supplementing with FOS could serve as a potential approach for managing CGS by altering the composition and functionality of gut microbiota.